BACKGROUND AND OBJECTIVES: The prevalence and significance of remission and relapse in children, adolescents, and young adults with lupus nephritis in the United States are poorly understood. Patterns and predictors of disease progression in a southeastern U.S. pediatric cohort with severe lupus nephritis are presented. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: Individuals age 21 or less with kidney biopsy-proven lupus nephritis followed in the Glomerular Disease Collaborative Network were included. Cox regression models were used to evaluate predictors of relapse and end stage kidney disease (ESKD). RESULTS: Seventy-three subjects with a mean age of 15.6 +/- 3.4 yr were included. Five-year kidney survival was 77%. Complete and partial remission rates within 1 yr of induction therapy were 25 and 64%, respectively. Relapse and ESKD rates were similar between complete and partial responders. Relapse occurred in 35% of responders (complete or partial) in 45 +/- 32 mo. Disease relapse was a predictor of ESKD (HR = 10.12, P < 0.0001). Treatment resistance was documented in African Americans more often than non-African Americans (eight versus 0; P = 0.03). ESKD HR associated with treatment resistance was 6.25, P < 0.002. CONCLUSIONS: Remission whether complete or partial is associated with improved kidney survival in children with lupus nephritis. Nephritis relapse is a strong predictor of progression to ESKD. Treatment resistance portends a high risk of ESKD and disproportionately affects African American children with lupus nephritis.
BACKGROUND AND OBJECTIVES: The prevalence and significance of remission and relapse in children, adolescents, and young adults with lupus nephritis in the United States are poorly understood. Patterns and predictors of disease progression in a southeastern U.S. pediatric cohort with severe lupus nephritis are presented. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: Individuals age 21 or less with kidney biopsy-proven lupus nephritis followed in the Glomerular Disease Collaborative Network were included. Cox regression models were used to evaluate predictors of relapse and end stage kidney disease (ESKD). RESULTS: Seventy-three subjects with a mean age of 15.6 +/- 3.4 yr were included. Five-year kidney survival was 77%. Complete and partial remission rates within 1 yr of induction therapy were 25 and 64%, respectively. Relapse and ESKD rates were similar between complete and partial responders. Relapse occurred in 35% of responders (complete or partial) in 45 +/- 32 mo. Disease relapse was a predictor of ESKD (HR = 10.12, P < 0.0001). Treatment resistance was documented in African Americans more often than non-African Americans (eight versus 0; P = 0.03). ESKD HR associated with treatment resistance was 6.25, P < 0.002. CONCLUSIONS: Remission whether complete or partial is associated with improved kidney survival in children with lupus nephritis. Nephritis relapse is a strong predictor of progression to ESKD. Treatment resistance portends a high risk of ESKD and disproportionately affects African American children with lupus nephritis.
Authors: J P Ioannidis; K A Boki; M E Katsorida; A A Drosos; F N Skopouli; J N Boletis; H M Moutsopoulos Journal: Kidney Int Date: 2000-01 Impact factor: 10.612
Authors: Keith K Lau; Deborah P Jones; Margaret C Hastings; Lillian W Gaber; Bettina H Ault Journal: Pediatr Nephrol Date: 2006-03-29 Impact factor: 3.714
Authors: David Askenazi; Barry Myones; Ankur Kamdar; Robert Warren; Maria Perez; Marietta De Guzman; Anna Minta; M John Hicks; Arundhati Kale Journal: Pediatr Nephrol Date: 2007-03-03 Impact factor: 3.714
Authors: T M Chan; F K Li; C S Tang; R W Wong; G X Fang; Y L Ji; C S Lau; A K Wong; M K Tong; K W Chan; K N Lai Journal: N Engl J Med Date: 2000-10-19 Impact factor: 91.245
Authors: Yiann E Chen; Stephen M Korbet; Robert S Katz; Melvin M Schwartz; Edmund J Lewis Journal: Clin J Am Soc Nephrol Date: 2007-11-14 Impact factor: 8.237
Authors: L B Lewandowski; L E Schanberg; N Thielman; A Phuti; A A Kalla; I Okpechi; P Nourse; P Gajjar; G Faller; P Ambaram; H Reuter; G Spittal; C Scott Journal: Lupus Date: 2016-08-19 Impact factor: 2.911
Authors: Linda T Hiraki; Bing Lu; Steven R Alexander; Tamara Shaykevich; Graciela S Alarcón; Daniel H Solomon; Wolfgang C Winkelmayer; Karen H Costenbader Journal: Arthritis Rheum Date: 2011-07
Authors: J Bradley Layton; Susan L Hogan; Caroline E Jennette; Barbara Kenderes; Jenna Krisher; J Charles Jennette; William M McClellan Journal: Clin J Am Soc Nephrol Date: 2010-08-05 Impact factor: 8.237
Authors: Muir Morton; Sarah Edmonds; Aislinn M Doherty; Ajay Dhaygude; Matthew Helbert; Mike Venning Journal: Rheumatol Int Date: 2011-11-02 Impact factor: 2.631
Authors: Marie Tanzer; Cheryl Tran; Kassandra L Messer; Amber Kroeker; Emily Herreshoff; Larysa Wickman; Courtney Harkness; Peter Song; Debbie S Gipson Journal: Arthritis Care Res (Hoboken) Date: 2013-03 Impact factor: 4.794
Authors: Luis Fernando Pinto-Peñaranda; Vladimir Duque-Caballero; Javier Darío Márquez-Hernández; Carolina Muñoz-Grajales; Carlos Jaime Velásquez-Franco Journal: Clin Rheumatol Date: 2015-01-17 Impact factor: 2.980
Authors: X Liao; J Ren; A Reihl; T Pirapakaran; B Sreekumar; T E Cecere; C M Reilly; X M Luo Journal: Clin Exp Immunol Date: 2017-08-18 Impact factor: 4.330